Asante Gold
CNSX:ASEAsante Gold Corporation, a mineral exploration company, engages in the acquisition, exploration, and development of mineral resource properties in the Republic of Ghana. It holds 100% interest in the Fahiakoba concession situated in the Ashanti and Central regions in the Republic of Ghana; and 90% interest in the Bibiani gold mine located in the western region of Ghana. The company also has an option to acquire a 100% interest in the Betenase permit located in Ghana; 90% interest in the Kubi Mining lease located in southwest Ghana; and 100% interest in the Keyhole Gold project. Asante Gold Corporation was incorporated in 2011 and is based in Vancouver, Canada.
Burning Rock Biotech
NASDAQ:BNRBurning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.
West Red Lake Gold Mines
CNSX:RLGWest Red Lake Gold Mines Inc., acquires, explores for, and develops gold deposits in Canada. It holds interests in the West Red Lake project that includes three contiguous properties comprising the Mount Jamie Mine, Rowan Mine, and Red Summit Mine properties covering an area of 3,100 hectares located in Red Lake mining division, District of Kenora (Patricia Portion), Northwestern Ontario. The company was formerly known as Hy Lake Gold Inc. and changed its name to West Red Lake Gold Mines Inc. in May 2012. The company was incorporated in 1991 and is based in Toronto, Canada.